Exbio — Research products — Antibodies — Tags and labels — Anti-c-Myc tag FITC

Anti-c-Myc tag FITC

Regulatory status

RUO

Antigen

c-Myc tag

Clone

9E10

Format

FITC

Reactivity

Tagged fusion proteins in all species, Human

Application

FC, FC-IC (QC tested)

Excitation laser

blue (488 nm)

Variant

0.1 mg

1F-433-C100

In stock

254.10 USD

0.025 mg

1F-433-C025

Delivery 1 week

127.05 USD

Variant

0.1 mg

1F-433-C100

In stock

254.10 USD

0.025 mg

1F-433-C025

Delivery 1 week

127.05 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The antibody 9E10 can be used to detect the c-Myc tag.

Application

FC, FC-IC (QC tested)

Application details

Flow cytometry: Intracellular or extracellular staining, depending on particular expression. Recommended dilution: 1-5 μg/ml.

Reactivity

Tagged fusion proteins in all species, Human

Immunogen

Synthetic peptide sequence (AEEQKLISEEDLL) corresponding to the C-terminal region of human c-Myc.

Concentration

1 mg/ml

Preparation

Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

bHLH, MRTL, MYCC

Antigen description

The c-myc gene (8q24 on human chromosome) is the cellular homologue of the v-myc gene originally isolated from an avian myelocytomatosis virus. The c-Myc protein is a transcription factor (nuclear localization). c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin-dependent kinase, ERK2 and C-Jun N-terminal Kinase (JNK) in cell proliferation and cell cycle regulation. In normal cells the expression of c-Myc is tightly regulated but in human cancers c-Myc is frequently deregulated. c-Myc is also essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells.

Entrez Gene ID 4609

UniProt ID P01106

Flow cytometry analysis of transfected LST-1-c-Myc in HEK-293 cells (red) compared with nontransfected HEK-293 cells (blue) using mouse monoclonal anti-c-Myc (9E10) FITC.

Flow cytometry analysis (intracellular staining) of transfected LST-1-c-Myc in HEK-293 cells (red-filled) compared with nontransfected HEK-293 cells (black-dashed) using mouse monoclonal anti-c-Myc (9E10) FITC.

General references:

Persson H, Hennighausen L, Taub R, DeGrado W, Leder P: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science. 1984 Aug 17;225(4663):687-93.
PubMed

Evan GI et al. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-6.

Spandidos DA et al. 1987. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res 7:1299-304.

Prendergast GC. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18(19):2967-2987.

Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. 1999. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253(1): 63-77.

Boxer LM, Dang CV. 2001. Translocations involving c-myc and c-myc function. Oncogene 20(40):5595-5610.

Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21(21): 3414-3421.

Product specific references:

Wang X, Campoli M, Ko E, Luo W, Ferrone S: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004 Nov;294(1-2):23-35.
PubMed

Hilpert K, Hansen G, Wessner H, Kuttner G, Welfle K, Seifert M, Hohne W: Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Eng. 2001 Oct;14(10):803-6.
PubMed

Cermák L, Símová S, Pintzas A, Horejsí V, Andera L: Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells. Roles of transcription Daxx expression, and adhesion molecules. J Biol Chem. 2002 Mar 8;277(10):7955-61.
PubMed

Jelínková I, Šafaříková B, Vondálová Blanařová O, Skender B, Hofmanová J, Sova P, Moyer MP, Kozubík A, Kolář Z, Ehrmann J, Hyršlová Vaculová A: Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway. Biochem Pharmacol. 2014 Dec 1;92(3):415-24.
PubMed

Siegel J, Brandner G, Hess RD: Cross-reactivity of the monoclonal antibody 9E10 with murine c-MYC. Int J Oncol. 1998 Dec;13(6):1259-62.
PubMed

Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, Benistant C: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. J Cell Biol. 2008 Aug 11;182(3):603-14.
PubMed

Baggio R, Burgstaller P, Hale SP, Putney AR, Lane M, Lipovsek D, Wright MC, Roberts RW, Liu R, Szostak JW, Wagner RW: Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit. 2002 May-Jun;15(3):126-34.
PubMed

Fujiwara K, Poikonen K, Aleman L, Valtavaara M, Saksela K, Mayer BJ: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. Biochemistry. 2002 Oct 22;41(42):12729-38.
PubMed

Svadlenka J, Brazina J, Hanzlikova H, Cermak L, Andera L: Multifunctional adaptor protein Daxx interacts with chromatin-remodelling ATPase Brg1. Biochem Biophys Rep. 2015 Dec 30;5:246-252.
PubMed

Ta N, Qu C, Wu H, Zhang D, Sun T, Li Y, Wang J, Wang X, Tang T, Chen Q, Liu L: Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2022 Sep 6;119(36):e2117396119.
PubMed

Pesch T, Bonati L, Kelton W, Parola C, Ehling RA, Csepregi L, Kitamura D, Reddy ST: Molecular design, optimization, and genomic integration of chimeric B cell receptors in murine B cells. Front Immunol. 2019 Nov 14:10:2630.
PubMed

Oleari R, André V, Lettieri A, Tahir S, Roth L, Paganoni A, Eberini I, Parravicini C, Scagliotti V, Cotellessa L, Bedogni F, De Martini LB, Corridori MV, Gulli S, Augustin HG, Gaston-Massuet C, Hussain K, Cariboni A: A novel SEMA3G mutation in two siblings affected by syndromic GnRH deficiency. Neuroendocrinology 2021;111(5):421-441.
PubMed

Ma J, Jin C, Čančer M, Wang H, Ramachandran M, Yu D: Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus. Mol Ther Oncolytics 2021 May 5:21:356-366. doi: 10.1016/j.omto.2021.04.016. eCollection 2021 Jun 25.
PubMed

Laurent E, Sieber A, Salzer B, Wachernig A, Seigner J, Lehner M, Geyeregger R, Kratzer B, Jäger U, Kunert R, Pickl WF, Traxlmayr MW: Directed evolution of stabilized monomeric CD19 for monovalent CAR interaction studies and monitoring of CAR-T cell patients. ACS Synth Biol. 2021 May 21;10(5):1184-1198.
PubMed